Impact of disease‐modifying therapies on humoral and cellular immune‐responses following SARS‐CoV‐2 vaccination in MS patients
Abstract The impact of distinct disease‐modifying therapies (DMTs) on severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) vaccination efficacy in patients with multiple sclerosis (MS) is still enigmatic. In this prospective comparative study, we investigated humoral and cellular immune‐resp...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-07-01
|
| Series: | Clinical and Translational Science |
| Online Access: | https://doi.org/10.1111/cts.13256 |
| _version_ | 1828747763796410368 |
|---|---|
| author | Susan Trümpelmann Andreas Schulte‐Mecklenbeck Olga V. Steinberg Timo Wirth Manfred Fobker Lisa Lohmann Jan D. Lünemann Heinz Wiendl Catharina C. Gross Luisa Klotz |
| author_facet | Susan Trümpelmann Andreas Schulte‐Mecklenbeck Olga V. Steinberg Timo Wirth Manfred Fobker Lisa Lohmann Jan D. Lünemann Heinz Wiendl Catharina C. Gross Luisa Klotz |
| author_sort | Susan Trümpelmann |
| collection | DOAJ |
| description | Abstract The impact of distinct disease‐modifying therapies (DMTs) on severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) vaccination efficacy in patients with multiple sclerosis (MS) is still enigmatic. In this prospective comparative study, we investigated humoral and cellular immune‐responses in patients with MS receiving interferon beta, natalizumab, and ocrelizumab pre‐vaccination and 6 weeks post second SARS‐CoV‐2 vaccination. Healthy individuals and interferon beta‐treated patients generated robust humoral and cellular immune‐responses. Although humoral immune responses were diminished in ocrelizumab‐treated patients, cellular immune‐responses were reduced in natalizumab‐treated patients. Thus, both humoral and cellular immune responses should be closely monitored in patients on DMTs. Whereas patients with a poor cellular immune‐response may benefit from additional vaccination cycles, patients with a diminished humoral immune‐response may benefit from a treatment with SARS‐CoV‐2 antibodies in case of an infection. |
| first_indexed | 2024-04-14T04:47:02Z |
| format | Article |
| id | doaj.art-f05537ce2aae4b02889d23972f4c5898 |
| institution | Directory Open Access Journal |
| issn | 1752-8054 1752-8062 |
| language | English |
| last_indexed | 2024-04-14T04:47:02Z |
| publishDate | 2022-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Science |
| spelling | doaj.art-f05537ce2aae4b02889d23972f4c58982022-12-22T02:11:26ZengWileyClinical and Translational Science1752-80541752-80622022-07-011571606161210.1111/cts.13256Impact of disease‐modifying therapies on humoral and cellular immune‐responses following SARS‐CoV‐2 vaccination in MS patientsSusan Trümpelmann0Andreas Schulte‐Mecklenbeck1Olga V. Steinberg2Timo Wirth3Manfred Fobker4Lisa Lohmann5Jan D. Lünemann6Heinz Wiendl7Catharina C. Gross8Luisa Klotz9Department of Neurology with Institute of Translational Neurology University Hospital Münster Münster GermanyDepartment of Neurology with Institute of Translational Neurology University Hospital Münster Münster GermanyDepartment of Neurology with Institute of Translational Neurology University Hospital Münster Münster GermanyDepartment of Neurology with Institute of Translational Neurology University Hospital Münster Münster GermanyCentral Laboratories University Hospital Münster Münster GermanyDepartment of Neurology with Institute of Translational Neurology University Hospital Münster Münster GermanyDepartment of Neurology with Institute of Translational Neurology University Hospital Münster Münster GermanyDepartment of Neurology with Institute of Translational Neurology University Hospital Münster Münster GermanyDepartment of Neurology with Institute of Translational Neurology University Hospital Münster Münster GermanyDepartment of Neurology with Institute of Translational Neurology University Hospital Münster Münster GermanyAbstract The impact of distinct disease‐modifying therapies (DMTs) on severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) vaccination efficacy in patients with multiple sclerosis (MS) is still enigmatic. In this prospective comparative study, we investigated humoral and cellular immune‐responses in patients with MS receiving interferon beta, natalizumab, and ocrelizumab pre‐vaccination and 6 weeks post second SARS‐CoV‐2 vaccination. Healthy individuals and interferon beta‐treated patients generated robust humoral and cellular immune‐responses. Although humoral immune responses were diminished in ocrelizumab‐treated patients, cellular immune‐responses were reduced in natalizumab‐treated patients. Thus, both humoral and cellular immune responses should be closely monitored in patients on DMTs. Whereas patients with a poor cellular immune‐response may benefit from additional vaccination cycles, patients with a diminished humoral immune‐response may benefit from a treatment with SARS‐CoV‐2 antibodies in case of an infection.https://doi.org/10.1111/cts.13256 |
| spellingShingle | Susan Trümpelmann Andreas Schulte‐Mecklenbeck Olga V. Steinberg Timo Wirth Manfred Fobker Lisa Lohmann Jan D. Lünemann Heinz Wiendl Catharina C. Gross Luisa Klotz Impact of disease‐modifying therapies on humoral and cellular immune‐responses following SARS‐CoV‐2 vaccination in MS patients Clinical and Translational Science |
| title | Impact of disease‐modifying therapies on humoral and cellular immune‐responses following SARS‐CoV‐2 vaccination in MS patients |
| title_full | Impact of disease‐modifying therapies on humoral and cellular immune‐responses following SARS‐CoV‐2 vaccination in MS patients |
| title_fullStr | Impact of disease‐modifying therapies on humoral and cellular immune‐responses following SARS‐CoV‐2 vaccination in MS patients |
| title_full_unstemmed | Impact of disease‐modifying therapies on humoral and cellular immune‐responses following SARS‐CoV‐2 vaccination in MS patients |
| title_short | Impact of disease‐modifying therapies on humoral and cellular immune‐responses following SARS‐CoV‐2 vaccination in MS patients |
| title_sort | impact of disease modifying therapies on humoral and cellular immune responses following sars cov 2 vaccination in ms patients |
| url | https://doi.org/10.1111/cts.13256 |
| work_keys_str_mv | AT susantrumpelmann impactofdiseasemodifyingtherapiesonhumoralandcellularimmuneresponsesfollowingsarscov2vaccinationinmspatients AT andreasschultemecklenbeck impactofdiseasemodifyingtherapiesonhumoralandcellularimmuneresponsesfollowingsarscov2vaccinationinmspatients AT olgavsteinberg impactofdiseasemodifyingtherapiesonhumoralandcellularimmuneresponsesfollowingsarscov2vaccinationinmspatients AT timowirth impactofdiseasemodifyingtherapiesonhumoralandcellularimmuneresponsesfollowingsarscov2vaccinationinmspatients AT manfredfobker impactofdiseasemodifyingtherapiesonhumoralandcellularimmuneresponsesfollowingsarscov2vaccinationinmspatients AT lisalohmann impactofdiseasemodifyingtherapiesonhumoralandcellularimmuneresponsesfollowingsarscov2vaccinationinmspatients AT jandlunemann impactofdiseasemodifyingtherapiesonhumoralandcellularimmuneresponsesfollowingsarscov2vaccinationinmspatients AT heinzwiendl impactofdiseasemodifyingtherapiesonhumoralandcellularimmuneresponsesfollowingsarscov2vaccinationinmspatients AT catharinacgross impactofdiseasemodifyingtherapiesonhumoralandcellularimmuneresponsesfollowingsarscov2vaccinationinmspatients AT luisaklotz impactofdiseasemodifyingtherapiesonhumoralandcellularimmuneresponsesfollowingsarscov2vaccinationinmspatients |